Fight CRC Clinical Trial Finder
| NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT04185883 |
TitleSotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) | Phase
Phase 1
|
Date Added 2019-12-04 |
Location
Arizona, United States
California, United States Colorado, United States Connecticut, United States Florida, United States Georgia, United States Illinois, United States Indiana, United States Iowa, United States Maryland, United States Michigan, United States Missouri, United States New York, United States North Carolina, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States South Dakota, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States Australia Austria Belgium Canada Germany Italy Japan Korea, Republic of Netherlands Spain Taiwan United Kingdom |
Prior IO Allowed Yes |
CRC-directed No |
Status
Recruiting
|
Drugs
afatinib, AMG 404, Atezolizumab, carboplatin, pemetrexed, docetaxel, everolimus, FOLFIRI, FOLFOX, MVASI® (bevacizumab-awwb), palbociclib, panitumumab, Pembrolizumab, RMC-4630, Sotorasib, TNO155, Trametinib |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06850103 |
TitleSCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer with Oligometastases | Phase
Phase 2
|
Date Added 2025-03-25 |
Location |
Prior IO Allowed No |
CRC-directed Yes |
Status
Not yet recruiting
|
Drugs |
Tags
MSS/ MMRp
|
| NCT ID NCT06835179 |
TitleSBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer. | Phase
Phase 2
|
Date Added 2025-02-19 |
Location |
Prior IO Allowed No |
CRC-directed Yes |
Status
Not yet recruiting
|
Drugs |
Tags
MSS/ MMRp
|
| NCT ID NCT06794086 |
TitleSBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases | Phase
Phase 3
|
Date Added 2025-01-27 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSS/ MMRp
|
| NCT ID NCT03313778 |
TitleSafety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Participants With Resected Solid Tumors and in Combination With Pembrolizumab in Participants With Unresectable Solid Tumors | Phase
Phase 1
|
Date Added 2017-10-18 |
Location
Arizona, United States
California, United States District of Columbia, United States Florida, United States Massachusetts, United States New Jersey, United States New York, United States North Carolina, United States Ohio, United States Oregon, United States Pennsylvania, United States Tennessee, United States Australia Japan United Kingdom |
Prior IO Allowed No |
CRC-directed No |
Status
Recruiting
|
Drugs
mRNA-4157, Pembrolizumab, Keytruda |
Tags
MSS/ MMRp
|
| NCT ID NCT02617277 |
TitleSafety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours | Phase
Phase 1
|
Date Added 2015-11-30 |
Location
Colorado, United States
Florida, United States Tennessee, United States |
Prior IO Allowed Yes |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
AZD1775, MEDI4736 |
Tags
MSS/ MMRp
|
| NCT ID NCT05243862 |
TitleSafety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer. | Phase
Phase 2
|
Date Added 2022-02-17 |
Location
Arizona, United States
Florida, United States Minnesota, United States |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Atezolizumab, PolyPEPI1018, Tecentriq |
Tags
MSS/ MMRp
|
| NCT ID NCT06065371 |
TitleSacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy | Phase
Phase 1
|
Date Added 2023-10-03 |
Location
Michigan, United States
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
capecitabine, Sacituzumab govetican |
Tags
MSS/ MMRp
|
| NCT ID NCT03365882 |
TitleS1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery | Phase
Phase 2
|
Date Added 2017-12-07 |
Location
Alaska, United States
Arizona, United States Arkansas, United States California, United States Colorado, United States Connecticut, United States Florida, United States Georgia, United States Hawaii, United States Idaho, United States Illinois, United States Indiana, United States Iowa, United States Kansas, United States Kentucky, United States Louisiana, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Mississippi, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New Hampshire, United States New Jersey, United States New Mexico, United States North Carolina, United States North Dakota, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Rhode Island, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Vermont, United States Washington, United States West Virginia, United States Wisconsin, United States Wyoming, United States Puerto Rico |
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
cetuximab, HER-2 testing, Irinotecan Hydrochloride, Pertuzumab, Trastuzumab, Camptosar, Erbitux, Herceptin, Perjeta |
Tags
MSS/ MMRp
|
| NCT ID NCT05733611 |
TitleRP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC | Phase
Phase 2
|
Date Added 2023-02-17 |
Location |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs |
Tags
MSS/ MMRp
|
